{"url_path":"/sec/iccc/8-k/2026-07-09/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 **            **Results of Operations and Financial Condition.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-09","source_url":"https://www.sec.gov/Archives/edgar/data/811641/0001437749-26-023199-index.html","accession_number":"0001437749-26-023199","cik":"0000811641","ticker":"ICCC","issuer_name":"IMMUCELL CORP /DE/","edgar_url":"https://www.sec.gov/Archives/edgar/data/811641/0001437749-26-023199-index.html","primary_entity_key":"0000811641","primary_entity_name":"IMMUCELL CORP /DE/"},"word_count":137,"has_tables":true,"body_markdown":"**Item 2.02.**            **Results of Operations and Financial Condition.** \n\n \n\nOn July 9, 2026 ImmuCell Corporation (the \"Company\") issued a press release announcing a 11.5% increase in product sales in Q2 of 2026 as compared to Q2 of 2025, based on preliminary, unaudited sales results for the quarter ended June 30, 2026. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.\n\n \n\nThe information shall not be deemed \"filed\" for purposed of Section 18 of the Securities Exchange Act of 1934 (the \"Exchange Act\") or otherwise subject to liabilities of that section, not shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing."}